Benign prostatic hyperplasia (BPH) is a prevalent condition among elderly men, impacting their quality of life. Traditional treatments primarily targeted bladder outlet obstruction (BOO) through alpha-blockers and 5-alpha reductase inhibitors. Recent additions, such as muscarinic receptor antagonists and phosphodiesterase-5 inhibitor (PDE-5I) tadalafil, provide more options.
No takes yet. Share an insight, caveat, or question.
N. et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: